metformin has been researched along with simvastatin in 68 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.47) | 18.2507 |
| 2000's | 11 (16.18) | 29.6817 |
| 2010's | 41 (60.29) | 24.3611 |
| 2020's | 15 (22.06) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Taskinen, MR | 1 |
| Abourjaily, HM; Alsheikh-Ali, AA; Karas, RH | 1 |
| Hoogwerf, BJ; Nambi, V; Sprecher, DL | 1 |
| Bulcão, C; Ferreira, SR; Giuffrida, FM; Ribeiro-Filho, FF | 1 |
| Bulcão, C; Ribeiro-Filho, FF; Roberta Ferreira, SG; Sañudo, A | 1 |
| Arulmozhi, DK; Bodhankar, SL; Kurian, R; Veeranjaneyulu, A | 1 |
| De Flines, J; Jandrain, BJ; Radermecker, RP; Scheen, AJ | 1 |
| Akinci, B; Bayraktar, F; Comlekci, A; Demir, T; Ozcan, MA; Yener, S; Yesil, S; Yuksel, F | 1 |
| Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ | 2 |
| Asadi, N; Dehbashi, S; Ghaffarpasand, F; Kazerooni, T; Kazerooni, Y; Shojaei-Baghini, A | 1 |
| Gdula-Dymek, A; Krysiak, R; Okopien, B | 1 |
| Balink, H; de Graaf, W; Grond, J; Hemmelder, MH | 1 |
| Hart, RJ; Hunter, T; Raval, AD; Stuckey, B | 1 |
| Fouladi, RF; Navali, N; Nikpour, MA; Pourabolghasem, S | 1 |
| Krysiak, R; Okopien, B | 3 |
| Cai, L; Farabaugh, J; Farber, L; Li, F; Zhang, D | 1 |
| Banaszewska, B; Duleba, A; Karakas, SE; Pawelczyk, L; Spaczynski, RZ | 1 |
| Björnsson, E; Enders, F; Lindor, KD; Suwanwalaikorn, S; Treeprasertsuk, S | 1 |
| Gao, Q; Shen, S; Wang, Y; Xia, Yj; Yi, L; Zhang, C; Zhang, X | 1 |
| Babcook, MA; Daneshgari, F; Flask, CA; Fu, P; Gupta, S; Lindner, DJ; MacLennan, GT; Molter, JP; Oak, CZ; Parker, Y; Puchowicz, MA; Shukla, S; Vazquez, EJ | 1 |
| Almasan, A; Babcook, MA; Daneshgari, F; Fujioka, H; Gupta, S; Nanavaty, RR; Shukla, S; Sramkoski, RM | 1 |
| Chen, XY; Lan, D; Li, T; Liu, LM; Tian, KL; Wu, Y; Yang, GM; Zhu, Y | 1 |
| Choudhry, NK; Gagne, JJ; Kesselheim, AS; Landon, J; Wang, B | 1 |
| Bourre, B; Lefaucheur, R; Maltête, D; Ozkul-Wermester, O; Wallon, D | 1 |
| Bednarska-Czerwińska, A; Kowalcze, K; Krysiak, R; Okopień, B | 1 |
| Bläuer, M; Murtola, TJ; Pennanen, P; Savinainen, K; Syvälä, H; Tammela, TLJ; Ylikomi, T | 1 |
| Klein, JD; Sands, JM | 1 |
| Fukuchi, Y; Kamel, WA; Maki, K; Matsuo, K; Muto, A; Nobusue, H; Onishi, N; Saya, H; Shimizu, T; Sugihara, E; Yamaguchi-Iwai, S | 1 |
| El-Zaher, AA; Elkady, EF; Elwy, HM; Saleh, MAEM | 1 |
| Aicher, B; Ammer, N; Britz, H; Hanke, N; Lehr, T; Moj, D; Sindermann, H; Teifel, M; Wojtyniak, JG | 1 |
| Ampuero, J; Del Campo, JA; Gallego, P; Gallego-Durán, R; García-Valdecasas, M; Gil-Gómez, A; Grande, L; Muntané, J; Padillo, FJ; Pastor, H; Rojas, Á; Romero-Gómez, M | 1 |
| Mahmud, G; Malik, M; Tasnim, N | 1 |
| Bech, AP; Nijenhuis, T; Wetzels, JFM | 1 |
| Hefzy, E; Seyam, E | 1 |
| Bumbasirevic, V; Ciric, D; Kravic-Stevovic, T; Martinovic, T; Petricevic, S; Trajkovic, V | 1 |
| Gu, YY; Guan, QB; Jing, F; Yang, S; Yu, CX | 1 |
| Bhakoo, KK; Boominathan, R; Chan, K; Cheng, P; Goggi, JL; Haslop, A; Robins, EG; Soh, V | 1 |
| Kim, JS; Rodriguez, GC; Rosales, R; Thaete, LG; Turbov, J | 1 |
| Bakar, NKA; Kafeenah, HIS; Osman, R | 1 |
| Alhambra-Expósito, MR; Barrera-Martín, A; Blanco-Acevedo, C; Castaño, JP; Dios, E; Fanciulli, A; Fuentes-Fayos, AC; Gahete, MD; Gálvez-Moreno, MA; Granata, R; Herrera-Martínez, AD; Kineman, RD; L-López, F; Luque, RM; Moreno-Moreno, P; Solivera, J; Soto-Moreno, A; Vázquez-Borrego, MC; Venegas-Moreno, E | 1 |
| d'Auriol, M; de Souza Santos, LV; Jacob, RS; Lange, LC; Lebron, YAR; Moreira, VR | 1 |
| Brunicardi, FC; Creeden, JF; Damoiseaux, R; Erhardt, P; Kalinoski, A; Liu, SH; Markowiak, S; Nemunaitis, J; Sanchez, R; Sutton, JM; Yu, J; Zhang, JT | 1 |
| Hansen, HS; Jessen, JB; Johannsen, ML; Munkboel, CH; Styrishave, B | 1 |
| Glick, A; Johnson, C; Sista, V | 1 |
| Meng, J; Zhu, Y | 1 |
| Chen, L; Liu, Y; Shao, Y; Xie, J; Zhu, G | 1 |
| Ćosić, V; Jakab, J; Mikšić, Š; Miškić, B; Nakić, D; Tušek, I; Včev, A; Volarić, N; Zjalić, M | 1 |
| da Silva, SVS; de Carvalho, WC; de Freitas Santos Júnior, A; de Jesus, ACL; de Sousa, TL; Dos Santos, LC; Korn, MDGA; Santos, DCMB; Souza, LA | 1 |
| Kassie, GM; Kerr, M; Moffat, A; Pratt, N; Roughead, EE | 1 |
| Chen, H; Gao, X; Li, J; Li, Y; Liu, J; Liu, P; Ren, Y; Song, S; Wang, B; Wang, H; Wang, R; Wang, Y; Zhang, M | 1 |
| Castro-Santos, P; Díaz-Peña, R; Olloquequi, J | 1 |
| Bumbasirevic, V; Ciric, D; Jovanovic, S; Kravic-Stevovic, T; Martinovic, T; Petricevic, S; Trajkovic, V | 1 |
| Blanco-Acevedo, C; Castaño, JP; Doval-Rosa, C; Fuentes-Fayos, AC; G-García, ME; Gahete, MD; Jiménez-Vacas, JM; López, M; Luque, RM; Martín-Colom, J; Montero-Hidalgo, AJ; Ortega-Salas, RM; Peralbo-Santaella, E; Pérez-Gómez, JM; Sánchez-Sánchez, R; Solivera, J; Tena-Sempere, M; Toledano-Delgado, Á; Torres, E | 1 |
| Hao, SL; Meng, XY; Zhang, CL | 1 |
9 review(s) available for metformin and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Strategies for the management of diabetic dyslipidaemia.
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Risk Factors; Simvastatin | 1999 |
A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.
Topics: Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Hyperinsulinism; Hypertension; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metabolic Syndrome; Metformin; Motor Activity; Obesity; Simvastatin; Thiazoles; Thiazolidinediones; Weight Loss | 2002 |
Statins for women with polycystic ovary syndrome not actively trying to conceive.
Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Hirsutism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Hypoglycemic Agents; Menstruation Disturbances; Metformin; Polycystic Ovary Syndrome; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Young Adult | 2011 |
Physiological insights into novel therapies for nephrogenic diabetes insipidus.
Topics: Adenylate Kinase; Animals; Aquaporin 2; Diabetes Insipidus, Nephrogenic; Erlotinib Hydrochloride; Humans; Metformin; Mutation; Phosphorylation; Receptors, Vasopressin; Sildenafil Citrate; Simvastatin | 2016 |
The Effect of Statins on Levels of Dehydroepiandrosterone (DHEA) in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.
Topics: Adult; Atorvastatin; China; Dehydroepiandrosterone; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Middle Aged; Polycystic Ovary Syndrome; Simvastatin | 2019 |
Efficacy of simvastatin plus metformin for polycystic ovary syndrome: A meta-analysis of randomized controlled trials.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Simvastatin | 2021 |
The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome: A meta-analysis and systematic review.
Topics: Blood Glucose; Cholesterol; Drug Therapy, Combination; Female; Gonadal Steroid Hormones; Humans; Insulin; Lipoproteins, LDL; Metformin; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2021 |
Comparison of different drug for reducing testosterone levels in women with polycystic ovary syndrome: A systematic review and network meta-analysis.
Topics: Atorvastatin; Female; Humans; Metformin; Network Meta-Analysis; Polycystic Ovary Syndrome; Simvastatin; Spironolactone; Testosterone | 2023 |
16 trial(s) available for metformin and simvastatin
| Article | Year |
|---|---|
Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity?
Topics: Adiponectin; Adolescent; Adult; Aged; Anticholesteremic Agents; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Female; Humans; Hypoglycemic Agents; Leptin; Male; Metabolic Syndrome; Metformin; Middle Aged; Simvastatin | 2007 |
Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Biomarkers; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Female; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Male; Metabolic Syndrome; Metformin; Middle Aged; Simvastatin | 2007 |
Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Pressure; Carboxypeptidase B2; CD40 Ligand; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Simvastatin; Thiazolidinediones | 2009 |
Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial.
Topics: Adult; Cardiovascular Diseases; Dehydroepiandrosterone Sulfate; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Hypoglycemic Agents; Lipids; Metformin; Polycystic Ovary Syndrome; Prospective Studies; Risk Factors; Sex Hormone-Binding Globulin; Simvastatin; Testosterone | 2009 |
Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Anticholesteremic Agents; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Combination; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Metformin; Placebos; Polycystic Ovary Syndrome; Simvastatin; Testosterone; Young Adult | 2010 |
Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.
Topics: Blood Glucose; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenofibrate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Lymphocytes; Male; Metformin; Middle Aged; Monocytes; Prospective Studies; Simvastatin; Systemic Inflammatory Response Syndrome | 2011 |
Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment.
Topics: Adult; C-Reactive Protein; Drug Therapy, Combination; Female; Hirsutism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Hypoglycemic Agents; Lipoproteins, LDL; Metformin; Polycystic Ovary Syndrome; Simvastatin; Treatment Outcome | 2011 |
Therapeutic effects of biguanide vs. statin in polycystic ovary syndrome: a randomized clinical trial.
Topics: Adult; Anticholesteremic Agents; Biguanides; Blood Glucose; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Simvastatin; Treatment Outcome; Young Adult | 2011 |
Haemostatic effects of metformin in simvastatin-treated volunteers with impaired fasting glucose.
Topics: Antigens; Blood Coagulation; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Factor VII; Fasting; Female; Fibrinogen; Fibrinolysis; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Prediabetic State; Simvastatin | 2012 |
The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Drug Therapy, Combination; Fasting; Glucose Metabolism Disorders; Humans; Hypoglycemic Agents; Interleukins; Metformin; Middle Aged; Monocytes; Secretory Rate; Simvastatin; Tumor Necrosis Factor-alpha; Young Adult | 2013 |
Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose.
Topics: Anti-Inflammatory Agents; Biomarkers; Blood Glucose; C-Reactive Protein; Cytokines; Drug Synergism; Fasting; Female; Glucose Metabolism Disorders; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inflammation Mediators; Intercellular Adhesion Molecule-1; Lipids; Lymphocytes; Male; Metformin; Middle Aged; Poland; Simvastatin; Time Factors; Treatment Outcome | 2012 |
Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies.
Topics: Adult; Drug Therapy, Combination; Fatty Acid-Binding Proteins; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Polycystic Ovary Syndrome; Retinol-Binding Proteins, Plasma; Simvastatin; Young Adult | 2013 |
A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biotransformation; Computer Simulation; Doxorubicin; Drug Interactions; Female; Gonadotropin-Releasing Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Biological; Octamer Transcription Factor-2; Simvastatin; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2018 |
Effect of Metformin Alone Compared with Metformin Plus Simvastatin on Polycystic Ovarian Syndrome in Pakistani Women.
Topics: Adolescent; Adult; Drug Therapy, Combination; Female; Follicle Stimulating Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lipids; Metformin; Middle Aged; Ovary; Pakistan; Polycystic Ovary Syndrome; Simvastatin; Testosterone; Treatment Outcome | 2018 |
Effects of sildenafil, metformin, and simvastatin on ADH-independent urine concentration in healthy volunteers.
Topics: Adult; Diabetes Insipidus, Nephrogenic; Female; Healthy Volunteers; Humans; Kidney; Male; Metformin; Neurophysins; Osmolar Concentration; Protein Precursors; Sildenafil Citrate; Simvastatin; Urine; Vasopressins; Young Adult | 2018 |
Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome.
Topics: Adolescent; Anticholesteremic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Ovary; Polycystic Ovary Syndrome; Simvastatin; Young Adult | 2018 |
43 other study(ies) available for metformin and simvastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose).
Topics: Acarbose; Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Atorvastatin; Chromans; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrroles; Simvastatin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metformin; Mice; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Simvastatin; Streptozocin; Sulfonylurea Compounds; Thiazolidinediones; Triglycerides | 2008 |
[Optimisation of pharmacological therapy in a patient with a newly diagnosed type 2 diabetes].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Decision Making; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Simvastatin | 2009 |
Scintigraphic diagnosis of Erdheim-Chester disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Erdheim-Chester Disease; Gated Blood-Pool Imaging; Humans; Hydrochlorothiazide; Hypoglycemic Agents; Hypolipidemic Agents; Imidazoles; Knee Joint; Losartan; Male; Metformin; Positron-Emission Tomography; Prostatic Neoplasms; Simvastatin | 2011 |
A new methodology for high drug loading wet granulation formulation development.
Topics: Animals; Dogs; Drug Compounding; Etoricoxib; Excipients; Metformin; Particle Size; Polymers; Pyridines; Simvastatin; Solubility; Sulfones; Wettability | 2013 |
NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Cause of Death; Chi-Square Distribution; Decision Support Techniques; Fatty Liver; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Liver Cirrhosis; Logistic Models; Male; Metformin; Middle Aged; Minnesota; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Odds Ratio; Predictive Value of Tests; Prognosis; Risk Factors; Severity of Illness Index; Simvastatin; Time Factors; Young Adult | 2013 |
Dehydroepiandrosterone induces ovarian and uterine hyperfibrosis in female rats.
Topics: Animals; Dehydroepiandrosterone; Female; Fibrosis; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Ovarian Diseases; Polycystic Ovary Syndrome; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta; Uterine Diseases | 2013 |
Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Movement; Drug Synergism; Humans; Hypoglycemic Agents; Male; Metformin; Mice; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Simvastatin | 2014 |
Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Autophagy; Cell Line, Tumor; Chloroquine; Drug Combinations; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; Imidazoles; Indoles; Male; Metformin; Microtubule-Associated Proteins; Necrosis; Prostate; Prostatic Neoplasms, Castration-Resistant; Receptor-Interacting Protein Serine-Threonine Kinases; RNA, Small Interfering; Sequestosome-1 Protein; Signal Transduction; Simvastatin | 2014 |
Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Connexins; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Drug Therapy, Combination; Female; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; MicroRNAs; Muscle, Smooth, Vascular; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Renal Artery; rho-Associated Kinases; Simvastatin; Vasculitis | 2015 |
Availability and utilization of cardiovascular fixed-dose combination drugs in the United States.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Lisinopril; Metformin; Practice Patterns, Physicians'; Simvastatin; United States; United States Food and Drug Administration | 2015 |
Stroke mimicking relapse in a patient with CLIPPERS syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Brain Stem; Encephalomyelitis; Gadolinium; Humans; Hypoglycemic Agents; Inflammation; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Recurrence; Simvastatin; Stroke | 2015 |
The Effect of Simvastatin on Plasma Steroid Hormone Levels in Metformin-Treated Women with Non-Classic Congenital Adrenal Hyperplasia.
Topics: Adrenal Hyperplasia, Congenital; Adult; Female; Gonadal Steroid Hormones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Middle Aged; Simvastatin | 2016 |
The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines.
Topics: Adenosine Triphosphate; Apoptosis; Autophagy; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Interactions; Epithelial Cells; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Male; Metformin; Necrosis; Prostate; Simvastatin | 2016 |
Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Metformin; Mice; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; rhoA GTP-Binding Protein; Signal Transduction; Simvastatin; Xenograft Model Antitumor Assays | 2017 |
A Versatile Liquid Chromatographic Method for the Simultaneous Determination of Metformin, Sitagliptin, Simvastatin, and Ezetimibe in Different Dosage Forms.
Topics: Chromatography, High Pressure Liquid; Dosage Forms; Ezetimibe; Limit of Detection; Metformin; Simvastatin; Sitagliptin Phosphate | 2018 |
Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.
Topics: Autophagy; Biomarkers, Tumor; Carcinoma, Hepatocellular; Caspase 3; Cell Line; Cell Proliferation; Cells, Cultured; Drug Therapy, Combination; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Liver Neoplasms; Metformin; Microtubule-Associated Proteins; PTEN Phosphohydrolase; Simvastatin; TOR Serine-Threonine Kinases; Tumor Protein, Translationally-Controlled 1 | 2018 |
Metformin exacerbates and simvastatin attenuates myelin damage in high fat diet-fed C57BL/6 J mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diet, High-Fat; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Mice; Mice, Inbred C57BL; Myelin Sheath; Sciatic Nerve; Simvastatin | 2018 |
Imaging the Proangiogenic Effects of Cardiovascular Drugs in a Diabetic Model of Limb Ischemia.
Topics: Animals; Cardiovascular Agents; Diabetes Mellitus, Experimental; Hindlimb; Immunohistochemistry; Ischemia; Magnetic Resonance Imaging; Male; Metformin; Mice; Mice, Inbred BALB C; Muscle, Skeletal; Oligopeptides; Simvastatin | 2019 |
Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth.
Topics: Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Drug Therapy, Combination; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Metformin; Simvastatin; TOR Serine-Threonine Kinases | 2019 |
Effect of Mobile Phase pH on the Electrospray Ionization Efficiency and Qualitative Analysis of Pharmaceuticals in ESI + LC-MS/MS.
Topics: Chromatography, Liquid; Hydrogen-Ion Concentration; Ions; Limit of Detection; Linear Models; Metformin; Models, Chemical; Reproducibility of Results; Simvastatin; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2019 |
Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Mice; Middle Aged; Neuroendocrine Tumors; Papio anubis; Pituitary Gland; Pituitary Neoplasms; Rats; Simvastatin; Somatostatin; Young Adult | 2020 |
Diazepam, metformin, omeprazole and simvastatin: a full discussion of individual and mixture acute toxicity.
Topics: Aliivibrio fischeri; Diazepam; Metformin; Omeprazole; Simvastatin; Toxicity Tests, Acute | 2020 |
Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Digoxin; Drug Combinations; Drug Repositioning; Drug Synergism; High-Throughput Screening Assays; Homeodomain Proteins; Humans; Male; Metformin; Mice; Molecular Targeted Therapy; Pancreatic Neoplasms; Simvastatin; Survivin; Trans-Activators | 2020 |
Oral anti-diabetic drugs as endocrine disruptors in vitro - No evidence for additive effects in binary mixtures.
Topics: Administration, Oral; Cell Line; Chromatography, Liquid; Drug Interactions; Endocrine Disruptors; Humans; Hypoglycemic Agents; Metformin; Simvastatin; Sitagliptin Phosphate; Steroids; Sulfonylurea Compounds; Tandem Mass Spectrometry | 2021 |
Oral Manifestations of Commonly Prescribed Drugs.
Topics: Albuterol; Amlodipine; Anticonvulsants; Antihypertensive Agents; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bronchodilator Agents; Deprescriptions; Drug Hypersensitivity; Fluorides; Gingival Overgrowth; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Hypoglycemic Agents; Lisinopril; Losartan; Metformin; Metoprolol; Mouth Diseases; Omeprazole; Oral Hygiene; Proton Pump Inhibitors; Simvastatin; Thyroxine; Toothpastes; Xerostomia | 2020 |
Effect of Metformin and Simvastatin in Inhibiting Proadipogenic Transcription Factors.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Fluorescent Antibody Technique; Gene Expression Profiling; Gene Expression Regulation; Immunohistochemistry; Lipid Metabolism; Metformin; Mice; Simvastatin; Transcription Factors; Transcriptome | 2021 |
Effect of losartan potassium, metformin hydrochloride, and simvastatin on in vitro bioaccessibility of Cu, Fe, Mn, and Zn in oat flour from Brazil.
Topics: Avena; Brazil; Flour; Humans; Losartan; Metformin; Micronutrients; Simvastatin; Zinc | 2022 |
Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case-Control Study with a Focus on Medicines Used in Primary Care.
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Amlodipine; Amphotericin B; Australia; Case-Control Studies; Ciprofloxacin; Diclofenac; Furosemide; Humans; Ibuprofen; Metformin; Naproxen; Omeprazole; Primary Health Care; Ramipril; Simvastatin; Spironolactone; Sulfamethoxazole; Telmisartan; Trimethoprim; Valacyclovir; Zoledronic Acid | 2022 |
Metformin and simvastatin synergistically suppress endothelin 1-induced hypoxia and angiogenesis in multiple cancer types.
Topics: Animals; Cell Line, Tumor; Endothelin-1; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Metformin; Mice; Neoplasms; Neovascularization, Pathologic; Simvastatin | 2023 |
Pharmacogenetic Variation and Its Clinical Relevance in a Latin American Rural Population.
Topics: DNA, Intergenic; Gene Frequency; Genetics, Population; HLA-G Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Latin America; Metformin; Pharmacogenetics; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Rural Population; Ryanodine Receptor Calcium Release Channel; Simvastatin; Solute Carrier Family 22 Member 5 | 2022 |
Effects of metformin and simvastatin treatment on ultrastructural features of liver macrophages in HFD mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Liver; Macrophages; Metformin; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Simvastatin | 2023 |
Metformin and simvastatin exert additive antitumour effects in glioblastoma via senescence-state: clinical and translational evidence.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Mice; Proto-Oncogene Proteins c-akt; Retrospective Studies; Simvastatin; Transforming Growth Factor beta | 2023 |